Molecular Profiling and Molecular Labeling of Inflammatory Myofibroblastic Tumor
Status
Conditions
Details and patient eligibility
About
Gene mutation is a research hotspot in the occurrence of multiple malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of genes related to inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.
Full description
Inflammatory myofibroblastic tumor（IMT）is a rare clinical mesenchymal tissue-derived tumor, which can occur in almost all organs and soft tissues, and is characterized by low-grade or borderline tumors.
The diagnosis of inflammatory myofibroblastic tumor is mainly based on histopathology and immunohistochemistry. The treatment is resistant to conventional chemotherapy and radiotherapy. The only curative treatment is complete surgical resection. When IMT shows typical cellular structural features in pathology, the diagnosis is relatively simple. However, in the presence of atypical features, the accurate diagnosis of IMT is still a challenge. Therefore, it is necessary to explore a better diagnostic method. Secondly, there is no individualized treatment method for aggressive IMT patients who relapse and metastasize after surgery. At present, gene mutation is a research hotspot in the occurrence of various malignant tumors. The somatic gene mutations of many different types of tumors not only help to study the tumorigenesis mechanism and molecular diagnosis, but also can be used as an ideal therapeutic target. Large-scale gene profiling studies performed by humans in various types of epithelial tumors have confirmed some new gene mutations. However, there are few reports on the detection of inflammatory myofibroblastic tumor, and humans have not yet understood its molecular content. Therefore, it is necessary to further use molecular detection methods to explore the molecular markers of IMT to facilitate its follow-up precise treatment plan.
Enrollment
Sex
Volunteers
Inclusion criteria
- From December 2009 to July 2019, patients who were pathologically diagnosed with inflammatory myofibroblastic tumor by Sun Yat-sen University Cancer Center；
- There are related pathological tissue wax blocks in Sun Yat-sen University Cancer Center;
- Patient clinical and prognosis tracking data are available.
Exclusion criteria
The patient who has a clinically detectable second primary malignant tumor.
Trial design
29 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Dongsheng Zhang, PhD; Yan Wang, M.M.
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal